Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.11 CAD
Change Today 0.00 / 0.00%
Volume 4.2K
CUR On Other Exchanges
As of 1:15 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

diagnocure inc (CUR) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/1/15 - C$0.25
52 Week Low
12/22/14 - C$0.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DIAGNOCURE INC (CUR)

Related News

No related news articles were found.

diagnocure inc (CUR) Related Businessweek News

No Related Businessweek News Found

diagnocure inc (CUR) Details

DiagnoCure Inc., a life sciences company, develops and commercializes cancer diagnostic tests for the detection and management of cancer. The company primarily focuses on molecular diagnostic tests. It offers PCA3 test for the diagnosis of prostate cancer; and Guanylyl Cyclase C (GCC) marker and Previstage GCC colorectal cancer staging test for use in colorectal cancer management. The company also provides gene expression and copy number variation analysis, mutation detection, SNP genotyping, and platform and laboratory environment services. DiagnoCure Inc. was founded in 1994 and is headquartered in Quebec, Canada.

10 Employees
Last Reported Date: 01/27/15
Founded in 1994

diagnocure inc (CUR) Top Compensated Officers

Co-Founder, President and Chief Medical Offic...
Total Annual Compensation: C$185.4K
Interim Chief Financial Officer and Senior Di...
Total Annual Compensation: C$133.6K
Compensation as of Fiscal Year 2014.

diagnocure inc (CUR) Key Developments

DiagnoCure Inc. expected to report Q3 2015 results on September 4, 2015. This event was calculated by Capital IQ (Created on June 25, 2015).

DiagnoCure Inc. expected to report Q3 2015 results on September 4, 2015. This event was calculated by Capital IQ (Created on June 25, 2015).

DiagnoCure Inc. Announces Earnings Results for the Six Months Ended April 30, 2015

DiagnoCure Inc. announced earnings results for the six months ended April 30, 2015. For the six months, the company’s total revenues were CAD 272,700, compared to CAD 277,462 million for the same period ended April 30, 2014. Net loss and comprehensive loss for the first six months ended April 30, 2015 was CAD 900,262, or CAD 0.02 loss per share, compared to a net loss and comprehensive loss of CAD 1.07 million, or CAD 0.02 loss per share, for the same period ended April 30, 2014.

DiagnoCure Inc. Announces Executive Changes

Also, as part of the corporation's continuing plan to improve efficiency and reduce expenses, DiagnoCure Inc. has reduced its Board of directors to three independent members. Mr. Andrew J. (Andy) Sheldon leaves the Board but will continue to provide advice on different matters. In addition, Dr. Yves Fradet, founder of the Corporation, has stepped down as Chairman and leaves the Board to concentrate on business and corporate development as President and Chief Medical Officer. Dr. Jacques Simoneau has been elected Chairman of the Board. As a consequence of these changes, a lead director is no longer required. Dr. Vincent R. Zurawski will join the Audit and Risk Management committee, which will be chaired by Dr. Louise Proulx. Corporate governance, human resources and nominating matters will be addressed directly by the Board. Mr. Richard Bordeleau will continue to report to the Board and work closely with Dr. Fradet advancing important leads in business development and merger activities.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CUR:CN C$0.11 CAD 0.00

CUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CUR.
View Industry Companies

Industry Analysis


Industry Average

Valuation CUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAGNOCURE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at